Orchestra BioMed Q2 revenue drops, net loss widens

Orchestra Biomed Holdings

10/08/2026 21:20

Overview
US biomedical innovator's Q2 revenue declined sharply, reflecting minimal product and partnership sales
Net loss for Q2 widened yr/yr, driven by higher R&D expenses for pivotal trials
Company received $35 mln in strategic capital, boosting cash balance to $110 mln

Outlook
Company expects to complete BACKBEAT Trial enrollment by end of Q3 2026
Primary data from BACKBEAT Trial targeted for Q2 2027
Company projects cash runway into Q4 2027 and through key milestones

Result Drivers
R&D SPENDING - Higher research and development costs, mainly for the BACKBEAT and Virtue SAB pivotal trials, drove increased expenses
CASH INFUSION - $35 mln in strategic capital from Medtronic and Ligand boosted cash balance and funded programs through next milestones
LOWER SG&A COSTS - Selling, general and administrative expenses fell due to decreased stock-based compensation

Company press release: ID:nGNX6mmYNv

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.38
 
Q2 Net Loss
 
$24.10 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Orchestra Biomed Holdings Inc is $10.00, about 135.8% above its August 7 closing price of $4.24

Reuters Recommended Reads
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)